Antibody Drug Conjugate Market by Mechanism of Action (CD30 Antibodies, ErbB2 Antibodies), Drugs, Technology, Indication, End User

Description

List of Tables

[195 Pages Report] The Antibody Drug Conjugate Market size was estimated at USD 5.60 billion in 2023 and expected to reach USD 6.48 billion in 2024, at a CAGR 16.12% to reach USD 15.96 billion by 2030.

The antibody drug conjugate (ADC) includes developing, manufacturing, and commercializing therapeutic molecules that combine monoclonal antibodies with cytotoxic agents. These hybrid compounds selectively target and eliminate cancer cells while minimizing toxicity to healthy tissue. ADCs are widely used in oncology due to their enhanced efficacy and reduced side effects compared to traditional chemotherapy. The continuous rise in cancer prevalence globally fuels the need for innovative therapies such as ADCs. However, the complexity of the manufacturing process for ADCs can be challenging, as they require multiple steps and stringent quality control measures to ensure product homogeneity and stability. Moreover, research is being conducted on applying ADC technologies to other diseases beyond oncology, including autoimmune disorders and infectious diseases, which is expected to encourage the utilization of ADCs by the end-use sectors worldwide.

KEY MARKET STATISTICS
Base Year [2023]	USD 5.60 billion
Estimated Year [2024]	USD 6.48 billion
Forecast Year [2030]	USD 15.96 billion
CAGR (%)	16.12%

Mechanism of Action: Increasing preference for ErbB2 antibodies (HER2) for effective treatment of breast and gastric cancer

CD30 antibodies are a class of antibody drug conjugates (ADCs) that target the CD30 antigen, which is overexpressed in several types of cancers such as anaplastic large cell lymphoma, Hodgkin's lymphoma, and other T-cell lymphomas. These ADCs have exhibited promising results in clinical trials and have been widely used for their efficiency and specificity in delivering cytotoxic agents to cancer cells while sparing healthy tissues. ErbB2 antibodies are another class of ADCs that target the human epidermal growth factor receptor 2 (HER2), which plays a crucial role in the proliferation of cancer cells. Overexpression of HER2 occurs in various malignancies, including breast cancer and gastric cancer. ErbB2-targeting ADCs have been effective in improving outcomes for patients suffering from these diseases where traditional therapies have failed.

Drugs: Penetration of Enhertu as a promising drug for targeted therapies in the oncology field

Adcetris (brentuximab vedotin) is employed for the treatment of various lymphoma subtypes, such as anaplastic large cell lymphoma (ALCL), Hodgkin's lymphoma (HL), and peripheral T-cell lymphomas (PTCL). Its clinical success is attributed to its ability to target CD30-expressing cancer cells with a potent cytotoxic agent known as monomethyl auristatin E (MMAE), leading to enhanced overall survival rates in patients with limited treatment options in the past. Blenrep (belantamab mafodotin-blmf) addresses an unmet need in treating relapsed or refractory multiple myeloma. It targets B-cell maturation antigen (BCMA) on malignant plasma cells by delivering a potent microtubule-disrupting agent called monomethyl auristatin F (MMAF). Enhertu (fam-trastuzumab deruxtecan-nxki) was developed for the treatment of metastatic HER2-positive breast cancer and has demonstrated significant advancement in progression-free survival as compared to standard therapies such as trastuzumab emtansine (T-DM1). Kadcyla (ado-trastuzumab emtansine) is a solution for patients with HER2-positive metastatic breast cancer. It is used in patients previously treated with trastuzumab and taxane therapy. Its unique mechanism of action involves the targeted delivery of a highly potent cytotoxic agent called DM1 to HER2-overexpressing tumor cells. Padcev (enfortumab vedotin-ejfv) is used to treat advanced urothelial cancer, representing a considerable unmet medical need. It selectively targets Nectin-4, an adhesion molecule highly expressed in urothelial cancers, and delivers the potent cytotoxic agent MMAE directly to tumor cells. Trodelvy (sacituzumab govitecan-hziy) addresses an unmet need in treating triple-negative breast cancer (TNBC), a subtype characterized by limited therapeutic options and poor prognosis.

Technology: Preference for linkerless technology for simplifying the manufacturing process and improving the stability of ADCs

The cleavable linker technology is designed to release the cytotoxic drug selectively within the tumor cells through specific enzymatic or chemical cleavage. This approach increases therapeutic efficacy while minimizing off-target toxicities. Linkerless ADCs employ direct conjugation of the cytotoxic drug to the antibody without using any additional linker molecules. This simplifies the manufacturing process and improves the stability and homogeneity of ADC products. Non-cleavable linkers are robust and stable, designed to remain intact within the bloodstream while releasing their cytotoxic payload upon internalization into targeted tumor cells. The advantage of non-cleavable linkers is their enhanced stability, reducing the risk of premature drug release and off-target toxicity. Cleavable linkers provide selective activation within tumor cells, limiting off-target toxicities; however, they may suffer from higher systemic instability than other technologies. Linkerless ADCs offer streamlined manufacturing processes and possible improvements in product homogeneity and may be less versatile due to direct conjugation requirements. Non-cleavable linkers offer increased stability within the bloodstream; however, they rely heavily on efficient antibody internalization for effective drug release.

Indication: Rapid usage of ADCs for efficient treatment of breast cancer

ADCs have emerged as a reliable therapy for blood cancers, including lymphoma, leukemia, and multiple myeloma, due to their ability to target tumor-specific antigens expressed on malignant cells while sparing normal hematopoietic cells. ADCs are gaining attention in breast cancer treatment due to their ability to target overexpressed receptors, including HER2. ADCs are widely used in treating leukemia, a blood cancer characterized by the rapid production of abnormal white blood cells. Lymphomas are cancers of the lymphatic system and include Hodgkin and non-Hodgkin subtypes. ADCs targeting specific antigens on malignant lymphocytes have effectively treated these cancers. Multiple myeloma is a type of cancer of plasma cells that affects bone marrow, and ADCs targeting B-cell maturation antigen (BCMA) show potential for treating this malignancy. ADCs also demonstrate potential in urothelial and bladder cancer treatment owing to their ability to target specific proteins overexpressed in these malignancies.

End User: Emerging use of ADCs by academic research institutes for novel developments

In academic research institutes, ADCs are essential in extending the understanding of cancer biology and therapeutic mechanisms. Researchers use ADCs to explore the complex interactions between tumor cells and the tumor microenvironment. Biopharmaceutical and biotechnology companies are at the forefront of ADC development and commercialization by investing heavily in R&D activities for discovering new antibody drug conjugate targets and payloads while improving drug-linker technologies. Hospitals also play a pivotal role in validating the effectiveness of ADCs through clinical trials. Specialized cancer centers serve as hubs for multidisciplinary expertise and state-of-the-art technologies that facilitate the translation of research findings into clinical practice. Specialized cancer centers foster an environment of collaboration between oncologists, pathologists, pharmacologists, and radiologists to enhance patient care through precision medicine.

Regional Insights

The antibody drug conjugates (ADCs) market is evolving in the Americas due to advancements in oncology and the need for targeted therapies. A robust research infrastructure and a favorable environment for innovation encourage growth of ADCs in the Americas. In the European Union (EU), centralized marketing authorization for ADCs is provided by the European Medicines Agency (EMA). The EU has observed several strategic collaborations to develop novel ADC therapy in recent years. The Middle East and Africa region presents untapped potential due to increasing healthcare expenditure and growing awareness of targeted therapies. Increasing R&D expenditure coupled with the prevalence of cancer are raising the need for ADCs in the APAC region. Additionally, introducing and utilizing advanced technologies for manufacturing ADCs is anticipated to increase their adoption by the end-use sectors across the globe.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Antibody Drug Conjugate Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Antibody Drug Conjugate Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Antibody Drug Conjugate Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., ADC Therapeutics SA, Ambrx Biopharma Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, BioNTech SE, Bristol-Myers Squibb Company, Byondis B.V., Celldex Therapeutics Inc., Creative Biolabs, Inc., Daiichi Sankyo Company, Limited, Eisai Co., Ltd., F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline PLC, Heidelberg Pharma AG, ImmunoGen, Inc., Innate Pharma SA, Innovent Biologics, Inc., Lonza Group Ltd., MacroGenics, Inc., MediLink Therapeutics, Merck KGaA, Mersana Therapeutics, Inc., Novartis AG, Oxford Biotherapeutics Limited, Pfizer, Inc., Pheon Therapeutics Ltd., Piramal Pharma Limited, Recipharm AB, Sanofi S.A., Sorrento Therapeutics, Inc., Tagworks Pharmaceuticals BV, Takeda Pharmaceutical Company Limited, Tubulis GmbH, and Zymeworks Inc..

Market Segmentation & Coverage

This research report categorizes the Antibody Drug Conjugate Market to forecast the revenues and analyze trends in each of the following sub-markets:

Mechanism of Action
- CD30 Antibodies
- ErbB2 Antibodies

Drugs
- Adcetris
- Blenrep
- Enhertu
- Kadcyla
- Padcev
- Trodelvy

Technology
- Cleavable Linker
- Linkerless
- Non-Cleavable Linker

Indication
- Blood Cancer
- Breast Cancer
- Lymphoma
- Multiple Myeloma
- Urothelial Cancer & Bladder Cancer

End User
- Academic Research Institutes
- Biopharmaceutical & Biotechnology Companies
- Hospitals
- Specialized Cancer Centers

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - Alaska
    - California
    - Florida
    - Illinois
    - Massachusetts
    - Michigan
    - Montana
    - Nevada
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Antibody Drug Conjugate Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Antibody Drug Conjugate Market?

3. What are the technology trends and regulatory frameworks in the Antibody Drug Conjugate Market?

4. What is the market share of the leading vendors in the Antibody Drug Conjugate Market?

5. Which modes and strategic moves are suitable for entering the Antibody Drug Conjugate Market?

Product Code: MRR-657F2A76F4DB

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increasing prevalence of cancer worldwide
  - 5.1.1.2. Growth in clinical trial activities and robust product pipeline
  - 5.1.1.3. Government support and initiatives encouraging research on cancer
- 5.1.2. Restraints
  - 5.1.2.1. High manufacturing cost of ADC and incidences of product recalls
- 5.1.3. Opportunities
  - 5.1.3.1. Increasing investment in biopharma R&D and introduction of novel ADCs
  - 5.1.3.2. Adoption of advanced technologies for developing ADC
- 5.1.4. Challenges
  - 5.1.4.1. Complexity in manufacturing of ADCs
5.2. Market Segmentation Analysis
- 5.2.1. Mechanism of Action: Increasing preference for ErbB2 antibodies (HER2) for effective treatment of breast and gastric cancer
- 5.2.2. Drugs: Penetration of Enhertu as a promising drug for targeted therapies in the oncology field
- 5.2.3. Technology: Preference for linkerless technology for simplifying the manufacturing process and improving the stability of ADCs
- 5.2.4. Indication: Rapid usage of ADCs for efficient treatment of breast cancer
- 5.2.5. End User: Emerging use of ADCs by academic research institutes for novel developments
5.3. Market Trend Analysis
- 5.3.1. Significant emphasis on securing approval for novel ADC drugs in the Americas
- 5.3.2. Cancer burden coupled with improving healthcare infrastructure in the APAC region
- 5.3.3. Supportive government initiatives for improved cancer research and treatment in the EMEA region
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework Analysis

6. Antibody Drug Conjugate Market, by Mechanism of Action

6.1. Introduction
6.2. CD30 Antibodies
6.3. ErbB2 Antibodies

7. Antibody Drug Conjugate Market, by Drugs

7.1. Introduction
7.2. Adcetris
7.3. Blenrep
7.4. Enhertu
7.5. Kadcyla
7.6. Padcev
7.7. Trodelvy

8. Antibody Drug Conjugate Market, by Technology

8.1. Introduction
8.2. Cleavable Linker
8.3. Linkerless
8.4. Non-Cleavable Linker

9. Antibody Drug Conjugate Market, by Indication

9.1. Introduction
9.2. Blood Cancer
9.3. Breast Cancer
9.4. Lymphoma
9.5. Multiple Myeloma
9.6. Urothelial Cancer & Bladder Cancer

10. Antibody Drug Conjugate Market, by End User

10.1. Introduction
10.2. Academic Research Institutes
10.3. Biopharmaceutical & Biotechnology Companies
10.4. Hospitals
10.5. Specialized Cancer Centers

11. Americas Antibody Drug Conjugate Market

11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States

12. Asia-Pacific Antibody Drug Conjugate Market

12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam

13. Europe, Middle East & Africa Antibody Drug Conjugate Market

13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom

14. Competitive Landscape

14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
- 14.3.1. Lonza to enhance commercial antibody-drug conjugate supply capacity
- 14.3.2. ENHERTU Recommended for Approval in the EU by CHMP for Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer
- 14.3.3. Pyxis Oncology Successfully Completes Acquisition of Apexigen
- 14.3.4. BeiGene and DualityBio Announce Partnership to Advance Differentiated Antibody Drug Conjugate (ADC) Therapy for Solid Tumors
- 14.3.5. Novartis-Backed Tagworks Raises USD 65 Million Series A to Further ADC, Click-to-Release Tech
- 14.3.6. Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering
- 14.3.7. Sony and Astellas Enter into Collaborative Research Agreement to Discover a Novel ADC Platform for the Oncology Field
- 14.3.8. BioNTech and DualityBio Form Global Strategic Partnership to Accelerate Development of Differentiated Antibody-Drug Conjugate Therapeutics for Solid Tumors
- 14.3.9. Pfizer Invests USD 43 Billion to Battle Cancer
- 14.3.10. AstraZeneca enters license agreement with KYM Biosciences for CMG901, a Claudin-18.2 antibody drug conjugate
- 14.3.11. U.S. FDA Approves Trodelvy in Pre-treated HR+/HER2- Metastatic Breast Cancer

15. Competitive Portfolio

15.1. Key Company Profiles
15.2. Key Product Portfolio